Antitumor benzoylsulfonamides

Abstract

The present invention provides antitumor compounds of the formula (I); and antitumor methods.

1 . A compound of Formula I: 
     
       
         
         
             
             
         
       
     
     where:
 A is phenyl, benzofuryl, cyclopentadienyl, cyclobutyl, or a cyclopentyl that is optionally substituted at one of the two carbons adjacent to the ring fusion of the cyclopentyl with an oxo moiety; 
 R 1  and R 2  are either both halo, both trifluoromethyl, or one is halo and the other is C 1 -C 6  alkyl; or 
 a pharmaceutically acceptable base addition salt thereof. 
 
   
   
       2 . The compound of  claim 1 , wherein the compound is a pharmaceutically acceptable base addition salt. 
   
   
       3 . The compound of  claim 2 , wherein the pharmaceutically acceptable base addition salt is a sodium salt. 
   
   
       4 . A method of treating susceptible neoplasms in a mammal comprising administering to a mammal in need of such treatment an oncolytically effective amount of a compound of Formula I: 
     
       
         
         
             
             
         
       
     
     where:
 A is phenyl, benzofuryl, cyclopentadienyl, cyclobutyl, or a cyclopentyl that is optionally substituted at one of the two carbons adjacent to the ring fusion of the cyclopentyl with an oxo moiety; 
 R 1  and R 2  are either both halo, both trifluoromethyl, or one is halo and the other is C 1 -C 6  alkyl; or 
 a pharmaceutically acceptable base addition salt thereof. 
 
   
   
       5 . A pharmaceutical formulation comprising a compound of Formula I: 
     
       
         
         
             
             
         
       
     
     where:
 A is phenyl, benzofuryl, cyclopentadienyl, cyclobutyl, or a cyclopentyl that is optionally substituted at one of the two carbons adjacent to the ring fusion of the cyclopentyl with an oxo moiety; 
 R 1  and R 2  are either both halo, both trifluoromethyl, or one is halo and the other is C 1 -C 6  alkyl; or 
 a pharmaceutically acceptable base addition salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient.